What is the recommended dose of Sovateletide for a patient weighing 50 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sovateltide Dosing for 50 kg Patient

For a 50 kg patient with acute cerebral ischemic stroke, administer sovateltide 0.3 µg/kg intravenously as a bolus over 1 minute, which equals 15 µg per dose.

Dosing Regimen

The complete treatment protocol consists of three doses per treatment day (0.9 µg/kg total daily dose), administered at 3 ± 1 hour intervals, on Days 1,3, and 6 following stroke onset. 1, 2

Specific Calculation for 50 kg Patient:

  • Single dose: 0.3 µg/kg × 50 kg = 15 µg per injection 1, 2
  • Daily total: 0.9 µg/kg × 50 kg = 45 µg (given as three 15 µg doses) 1, 2
  • Treatment days: Day 1, Day 3, and Day 6 1, 2

Administration Details

  • Route: Intravenous bolus 1, 2
  • Duration of injection: Over 1 minute 1
  • Timing between doses: 3 ± 1 hour intervals on each treatment day 1, 2
  • Window for initiation: Within 24 hours of stroke onset 2, 3

Clinical Context

This dosing was established in Phase III trials where patients received the investigational drug at approximately 18 hours after stroke onset, with a median baseline NIHSS of 9-10. 2 The regimen demonstrated significant efficacy with 22.67% more patients achieving mRS 0-2 at 90 days compared to control (OR 2.75,95% CI 1.37-5.57). 2

Sovateltide was well-tolerated with no drug-related adverse events and no effect on hemodynamic, biochemical, or hematological parameters at this dosing. 1 The safety profile showed similar rates of intracranial hemorrhage between sovateltide (8.75%) and control groups (8.97%), indicating no increased bleeding risk. 2

Important Caveats

  • This dosing applies specifically to acute cerebral ischemic stroke patients aged 18-78 years with NIHSS ≥6 and radiologic confirmation of stroke. 2
  • Patients receiving endovascular therapy, those with intracranial hemorrhage, or recurrent stroke were excluded from trials and should not receive this regimen. 2
  • No dose adjustment based on weight was used in clinical trials; the same 0.3 µg/kg dose was administered regardless of patient size. 1, 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.